AcelRx Pharmaceuticals, Inc. (ACRX) Lowered to “Strong Sell” at ValuEngine

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) was downgraded by research analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research note issued on Friday.

Other analysts have also recently issued reports about the stock. Jefferies Group LLC reiterated a “buy” rating and issued a $7.00 target price on shares of AcelRx Pharmaceuticals in a research note on Friday, July 14th. Roth Capital set a $13.00 target price on shares of AcelRx Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, August 2nd. Royal Bank Of Canada set a $6.00 target price on shares of AcelRx Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, August 25th. Stifel Nicolaus upgraded shares of AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, August 9th. Finally, HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of AcelRx Pharmaceuticals in a research note on Friday, August 4th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the stock. AcelRx Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $7.50.

Shares of AcelRx Pharmaceuticals (NASDAQ ACRX) traded up 3.33% on Friday, reaching $3.10. 1,116,705 shares of the company’s stock traded hands. The company’s 50-day moving average price is $3.12 and its 200 day moving average price is $2.81. AcelRx Pharmaceuticals has a one year low of $1.95 and a one year high of $4.08. The firm’s market cap is $140.68 million.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last posted its earnings results on Tuesday, August 1st. The specialty pharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.01). AcelRx Pharmaceuticals had a negative return on equity of 478.66% and a negative net margin of 319.19%. The firm had revenue of $2.66 million during the quarter, compared to analysts’ expectations of $2.63 million. On average, equities analysts forecast that AcelRx Pharmaceuticals will post ($1.13) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This story was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this story on another domain, it was illegally stolen and republished in violation of US and international copyright and trademark legislation. The original version of this story can be read at https://sportsperspectives.com/2017/09/15/acelrx-pharmaceuticals-inc-acrx-lowered-to-strong-sell-at-valuengine.html.

In related news, insider Pamela P. Palmer acquired 10,000 shares of the stock in a transaction dated Tuesday, August 22nd. The shares were purchased at an average price of $2.95 per share, for a total transaction of $29,500.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Life Sciences Maste Perceptive sold 875,000 shares of the firm’s stock in a transaction on Monday, June 19th. The shares were sold at an average price of $2.40, for a total transaction of $2,100,000.00. The disclosure for this sale can be found here. In the last 90 days, insiders have bought 37,000 shares of company stock worth $112,280. Corporate insiders own 28.10% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. purchased a new stake in shares of AcelRx Pharmaceuticals during the 2nd quarter valued at $530,000. Virtu KCG Holdings LLC raised its position in shares of AcelRx Pharmaceuticals by 600.9% during the 2nd quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock valued at $255,000 after buying an additional 101,742 shares in the last quarter. LMR Partners LLP purchased a new stake in shares of AcelRx Pharmaceuticals during the 2nd quarter valued at $319,000. WealthTrust Axiom LLC raised its position in shares of AcelRx Pharmaceuticals by 50.0% during the 2nd quarter. WealthTrust Axiom LLC now owns 210,000 shares of the specialty pharmaceutical company’s stock valued at $451,000 after buying an additional 70,000 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its position in shares of AcelRx Pharmaceuticals by 6.6% during the 1st quarter. Bank of New York Mellon Corp now owns 112,682 shares of the specialty pharmaceutical company’s stock valued at $355,000 after buying an additional 6,942 shares in the last quarter. Hedge funds and other institutional investors own 23.32% of the company’s stock.

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Analyst Recommendations for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply